Research programme: serotonin reuptake inhibitors/serotonin 1A receptor antagonists - Pfizer
Alternative Names: SSA-426; SSRI/5HT1A receptor antagonist - Wyeth; WAY-163426; WAY-211612; WAY-253752; WAY-426Latest Information Update: 04 Nov 2017
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Chromans; Quinolines
- Mechanism of Action 5-HT1A serotonin receptor antagonists; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder; Obsessive-compulsive disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obsessive-compulsive-disorders in USA (PO)